September 11
2024
Investors & media
Pure Biologics is a Polish biopharmaceutical company operating in the area of modern biological drugs. On the market since 2010, it was first in Poland to focus on developing new and innovative therapeutic molecules, not simply generic or biosimilar, based on antibodies and aptamers to be used in immuno-oncology and rare diseases applications.
In 2018, Pure Biologics entered the NewConnect market , and in 2020 transferred to the Main Market of the Warsaw Stock Exchange (as PURE).
Our team combines the recruitment of talent from renowned research groups, know-how acquired from years of activity, and an effective operating model, to drive the evolution of our own internal research projects, belonging to the most promising sectors of pharmaceutics.
Sources of funding for our therapeutic portfolio include grants from the European Union, complemented with revenue from contracted research delivered for pharmaceutical and biotechnology companies, as well as the capital invested by our company shareholders. The long-term strategy includes the partial reinvestment of profits from commercialization of our portfolio into our R&D activities and further development of the research program.
7,31%
270000 shares
eCapital sp. z o.o.
5,87%
216717 shares
Filip Jelen
President of the Board
86,82%
3205967 shares
Other shareholders
7,31%
270000 votes
eCapital sp. z o.o.
5,87%
216717 votes
Filip Jelen
President of the Board
86,82%
3205967 votes
Other shareholders
Share and votes table
| Shareholder | % shares | % votes |
|---|---|---|
| eCapital sp. zo.o. | 7,31 | 7,31 |
| Filip Jelen, President of the Board | 5,87 | 5,87 |
| Other shareholders | 86,82 | 86,82 |
Calendar of events and reports
-
RAPORT BIEŻĄCY ESPI 43/2024 – OŚWIADCZENIE O REJESTRACJI AKCJI SERII I W KDPW
-
RAPORT BIEŻĄCY ESPI 42/2024 – INFORMACJA O ZWOŁANIU NADZWYCZAJNEGO WALNEGO ZGROMADZENIA PURE BIOLOGICS S.A. WRAZ Z TREŚCIĄ PROJEKTÓW UCHWAŁ
-
RAPORT BIEŻĄCY ESPI 41/2024 – ZMIANA TERMINU PUBLIKACJI RAPORTU PÓŁROCZNEGO ZA I PÓŁROCZE 2024 R.
General meetings (PL)
Corporate governance (PL)
Memoranda and prospectuses (PL)
Documents prepared in connection with the application for the introduction of financial instruments to trading conducted by the Warsaw Stock Exchange S.A.
Contact for investors
Martyna Koj
Director of the Company Office
Investor Relations Representative
Address for submitting notifications
According to Art. 19 of the Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (MAR)